Beta Bionics (NASDAQ:BBNX) Upgraded by Wells Fargo & Company to “Strong-Buy” Rating

by · The Markets Daily

Wells Fargo & Company upgraded shares of Beta Bionics (NASDAQ:BBNX – Free Report) to a strong-buy rating in a research note published on Wednesday morning,Zacks reports.

BBNX has been the topic of several other research reports. Truist Financial reissued a “buy” rating and set a $23.00 target price (up from $22.00) on shares of Beta Bionics in a research report on Tuesday, September 15th. Bank of America increased their price target on shares of Beta Bionics from $18.00 to $20.00 and gave the company a “neutral” rating in a research note on Tuesday, September 15th. Wall Street Zen raised shares of Beta Bionics from a “sell” rating to a “hold” rating in a report on Saturday, September 19th. Robert W. Baird boosted their price objective on shares of Beta Bionics from $14.00 to $16.00 and gave the stock a “neutral” rating in a research report on Tuesday, September 15th. Finally, The Goldman Sachs Group upped their target price on shares of Beta Bionics from $17.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, July 15th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $22.45.

View Our Latest Report on BBNX

Beta Bionics Price Performance

NASDAQ:BBNX opened at $22.19 on Wednesday. The firm has a market capitalization of $998.33 million, a PE ratio of -13.45 and a beta of 3.37. The business’s fifty day moving average price is $17.98 and its 200 day moving average price is $14.29. Beta Bionics has a 12 month low of $8.80 and a 12 month high of $32.71.

Beta Bionics (NASDAQ:BBNX – Get Free Report) last announced its quarterly earnings results on Wednesday, July 29th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.09. The company had revenue of $32.01 million during the quarter. Beta Bionics had a negative return on equity of 26.30% and a negative net margin of 61.31%. As a group, equities analysts anticipate that Beta Bionics will post -2.06 EPS for the current year.

Insider Activity

In other Beta Bionics news, CFO Stephen Feider sold 6,675 shares of the stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $19.11, for a total transaction of $127,559.25. Following the completion of the sale, the chief financial officer directly owned 159,378 shares of the company’s stock, valued at approximately $3,045,713.58. This trade represents a 4.02% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Mike Mensinger sold 4,375 shares of the stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $19.11, for a total value of $83,606.25. Following the sale, the insider directly owned 180,040 shares of the company’s stock, valued at $3,440,564.40. The trade was a 2.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 107,327 shares of company stock valued at $2,070,421. Insiders own 5.30% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. BlackRock Inc. acquired a new stake in shares of Beta Bionics during the second quarter worth $52,340,000. Healthcare of Ontario Pension Plan Trust Fund purchased a new position in Beta Bionics in the 4th quarter valued at $40,437,000. Eversept Partners LP increased its stake in Beta Bionics by 108.6% in the 1st quarter. Eversept Partners LP now owns 1,414,838 shares of the company’s stock valued at $14,177,000 after buying an additional 736,576 shares during the period. 12 West Capital Management LP acquired a new position in Beta Bionics in the 4th quarter valued at $17,520,000. Finally, Bruce & Co. Inc. purchased a new position in Beta Bionics during the 1st quarter worth $5,518,000.

Key Beta Bionics News

Here are the key news stories impacting Beta Bionics this week:

  • Positive Sentiment: Beta Bionics announced a partnership with Senseonics to integrate its iLet Bionic Pancreas and mint automated insulin-delivery systems with Senseonics’ Eversense 365 continuous glucose monitor. The combined iLet-Eversense system is expected to launch commercially in the fourth quarter of 2026, potentially broadening customer choice and strengthening BBNX’s competitive position in automated diabetes management. Beta Bionics and Senseonics partnership
  • Neutral Sentiment: Analyst coverage remains generally constructive. Wells Fargo initiated coverage with an “overweight” rating and a $28 price target, while Leerink Partners raised its target to $27. However, the reported consensus target of approximately $22.45 suggests limited upside at recent trading levels. Beta Bionics analyst coverage
  • Negative Sentiment: Several law firms publicized a securities class-action lawsuit covering investors who purchased BBNX shares between July 30, 2025, and February 24, 2026. The complaints allege that Beta Bionics did not adequately disclose a June 2025 FDA Form 483 and more than 18,000 iLet-related complaints before later regulatory and product-safety disclosures. The allegations have not been proven, but the case raises potential regulatory, reputational and financial risks; the lead-plaintiff deadline is November 3, 2026. BBNX securities class-action notice
  • Negative Sentiment: Director Christy Jones sold 6,430 shares for approximately $147,890, reducing her position by 24.74%. The sale was conducted under a pre-arranged Rule 10b5-1 plan, which makes it a weaker discretionary bearish signal, but it adds to a broader pattern of insider selling without reported open-market purchases. SEC Form 4 filing

Beta Bionics Company Profile

(Get Free Report)

Beta Bionics, Inc is a medical technology company focused on developing automated insulin-delivery systems for people with diabetes. Its principal product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to simplify diabetes management by using continuous glucose monitoring data to adjust insulin dosing with limited user input.

The iLet Bionic Pancreas received clearance from the U.S. Food and Drug Administration in 2023 for use by people with type 1 diabetes.

Featured Stories